The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients

European Journal of Haematology

Volumn 95, Issue 5, 2015, Pages 436-441

  Ommen, Hans B ^a   Touzart, Aurore ^b   Macintyre, Elisabeth ^b   Kern, Wolfgang ^c   Haferlach, Torsten ^c   Haferlach, Claudia ^c   Tobal, Khalid ^d   Hokland, Peter ^a   Schnittger, Susanne ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b CNRS   (France)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

DEK NUP214; Minimal residual disease; Preemptive treatment; Relapse kinetics

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHILD; DEK NUP214 GENE; FLT3 GENE; FOLLOW UP; GENE; HUMAN; KINETICS; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANK SUM TEST; ALGORITHM; BIOLOGICAL MODEL; CHROMOSOME 6; CHROMOSOME 9; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENE TRANSLOCATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; RECURRENT DISEASE; SURVIVAL RATE;

DEK PROTEIN, HUMAN; NONHISTONE PROTEIN; NUCLEOPORIN; NUP214 PROTEIN, HUMAN; ONCOPROTEIN;

ADOLESCENT; ADULT; AGED; ALGORITHMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 9; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KINETICS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; RECURRENCE; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 84944515988     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12511     Document Type: Article

References (35)

1. Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 2013;121:1077-82.
2. Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM study group. J Clin Oncol 2013;31:599-607.
3. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007;92:1519-32.
4. Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 2011;117:2577-84.
5. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008;35:388-400.
6. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012;26:381-9.
7. Sockel K, Wermke M, Radke J, et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica 2011;96:1568-70.
8. Pozzi S, Geroldi S, Tedone E, et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013;160:503-9.
9. Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010;22:656-63.
10. Roug AS, Hansen MC, Nederby L, Hokland P. Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age. Br J Haematol 2014;167:162-76.
11. Ostergaard M, Nyvold CG, Jovanovic JV, et al. Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia 2011;25:1168-73.
12. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program. Leukemia 2003;17:2318-57.
13. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17:2474-86.
14. van der Velden VH, Boeckx N, Gonzalez M, et al. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - a study within the Europe against cancer program. Leukemia 2004;18:884-6.
15. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009;27:5195-201.
16. Ommen HB, Ostergaard M, Yan M, Braendstrup K, Zhang DE, Hokland P. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse. Eur J Haematol 2010;84:128-32.
17. Ommen HB, Hokland P, Haferlach T, et al. Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene. Br J Haematol 2014;165:618-28.
18. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012;120:2826-35.
19. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010;115:198-205.
20. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom medical research council trials. Blood 2010;116:354-65.
21. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials AML 10 and 12. J Clin Oncol 2010;28:2674-81.
22. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: International Agency for Research on Cancer IARC, 2008:439.
23. Ostergaard M, Stentoft J, Hokland P. A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia. Leuk Res 2004;28:1213-5.
24. Tobal K, Frost L, Liu Yin JA. Quantification of DEK-CAN fusion transcript by real-time reverse transcription polymerase reaction in patients with t(6;9) acute myeloid leukemia. Haematologica 2004;89:1267-9.
25. Garcon L, Libura M, Delabesse E, et al. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 2005;19:1338-44.
26. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999;13:1825-32.
27. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.
28. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
29. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 2003;5:96-102.
30. Ommen HB, Nyvold CG, Braendstrup K, et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008;141:782-91.
31. Tobal K, Saunders MJ, Grey MR, Yin JA. Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br J Haematol 1995;90:615-8.
32. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996;87:4789-96.
33. Slovak ML, Gundacker H, Bloomfield CD, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006;20:1295-7.
34. Bachas C, Schuurhuis GJ, Hollink IH, et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood 2010;116:2752-8.
35. Abdelhamid E, Preudhomme C, Helevaut N, et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res 2012;36:316-23.